# Absci CEO Aims to Build Biotech’s Answer to Apple Amid GLP-1 Drug Boom

The CEO of biotechnology company Absci is working to build what he describes as biotech’s version of Apple, according to a recent report. The effort comes as the overwhelming demand for GLP-1 weight loss drugs reshapes the pharmaceutical market, giving consumers more direct control over their own health.

The surge in GLP-1 medications has removed traditional barriers between patients and their medicine cabinets, the report states. This consumer-driven shift is empowering individuals to take charge of their treatment choices, a trend that Absci’s CEO is seeking to capitalize on by creating a company that merges technology and drug development in a more consumer-friendly model.

**Why this matters for biotech**

The GLP-1 class of drugs, originally developed for diabetes but now widely used for weight loss, has demonstrated that a single therapeutic category can fundamentally alter the economics and public perception of prescription medicine. For biotech companies, this creates both an opportunity and a challenge: the market is now more receptive to direct-to-consumer approaches and faster, more accessible drug delivery. Absci’s ambition to mirror Apple’s design and user-experience ethos suggests a broader push within the industry to treat patients as customers, not just clinical endpoints.

Source: [original report](https://www.fiercebiotech.com/biotech/his-parents-basement-your-medicine-cabinet-absci-ceo-endeavors-create-biotechs-apple)